Binding Site’s Immunologicals Group has completed a major expansion to their monoclonal antibody product offerings.
In addition to the established conjugated and unconjugated versions of the IgG4 Clone-HP6025 and the CD23 Clone BU-3438, Binding Site has recently introduced a number of new monolclonals focused on infectious diseases, including CMV, hepatitis (A, B, C, and D), herpes, HIV, rubella, and toxoplasma.
The products serve academic, clinical, biopharmaceutical and life-science researchers, as well as in-vitro diagnostic (IVD) manufacturing operations.
The antibodies exhibit high degrees of specificity, while demonstrating high levels of purity, extended shelf-life stability claims, and lot-to-lot consistencies, according to Binding Site. The infectious disease monoclonal antibodies are all available in a standard-sized 1.0mg fill format, while the rest come in a standard 0.2mg fill format. Bulk packaging and customer-specific packaging options are available.
Binding Site, a provider of specialized diagnostic products to clinicians and laboratory professionals worldwide, has offices and facilities in San Diego, CA.
(Source and Image Credit: The Binding Site, Inc.)
Filed Under: Drug Discovery
